Publications

Selected publications

For full list of publications : ORCID: 0000-0002-4871-8818

• Synergy and oxygen adaptation for development of next-generation probiotics
  Khan MT, Dwibedi C, Sundh D, Pradhan M, Kraft JD, Caesar R, Tremaroli V, Lorentzon M, Bäckhed F.  Nature (2023)
  We developed innovative technology to produce next-generation probiotics for human consumption from extremely oxygen sensitive human gut bacteria. In the article we describe the production of a formulation containing the anti-inflammatory Faecalibacterium prausnitzii, which is a dominant human gut bacterium, depleted in both inflammatory bowel diseases and metabolic diseases.
• 6α-hydroxylated bile acids mediate TGR5 signalling to improve glucose metabolism upon dietary fiber supplementation in mice.
  Makki, K., Brolin, H., Petersen, N., Henricsson, M., Christensen, D.P., Khan, M.T., Wahlström, A., Bergh, P.O., Tremaroli, V., Schoonjans, K., Marschall, H.U., Bäckhed, F. 
  Gut (2023)
  Here we unexpectedly demonstrated that in presence of dietary fiber the gut microbiota produces 6α-hydroxylated bile acids that improve glucose metabolism by activating TGR5/GLP-1 signaling. Illustrates our mechanistic/cell signaling work.
• Microbially produced imidazole propionate is associated with heart failure and mortality.
  Molinaro, A., Bel Lassen, P., Henricsson, M., Wu, H., Adriouch, S., Belda, E., Chakaroun, R., Nielsen, T., Bergh, P.O., Rouault, C., André, S., Marquet, F., Andreelli, F., Salem, J.E., Assmann, K., Bastard, J.P., Forslund, S., Le Chatelier, E., Falony, G., Pons, N., Prifti, E., Quinquis, B., Roume, H., Vieira-Silva, S., Hansen, T.H., Pedersen, H.K., Lewinter, C., Sønderskov, N.B.; MetaCardis Consortium, Køber, L., Vestergaard, H., Hansen, T., Zucker, J.D., Galan, P., Dumas, M.E., Raes, J., Oppert, J.M., Letunic, I., Nielsen, J., Bork, P., Ehrlich, S.D., Stumvoll, M., Pedersen, O., Aron-Wisneswky, J., Clément, K., Bäckhed, F.
  JACC Heart Failure (2023)
  Showed that imidazole propionate is elevated in patients with T2D and cardiovascular disease of different ethnicities.
• Dynamics of the normal gut microbiota: A longitudinal one-year population study in Sweden.
  Olsson, L.M., Boulund, F., Nilsson, S., Khan, M.T., Gummesson, A., Fagerberg, L., Engstrand, L., Perkins, R., Uhlén, M., Bergström, G., Tremaroli, V., Bäckhed. F. Cell Host Microbe (2022)  
  Here we define the normal variation of the gut microbiota in its two components: intra- and inter- individual. We define normal ranges for the abundance of the most dominant species in healthy individuals.
• Developmental trajectory of the healthy human gut microbiota during the first 5 years of life. 
  Roswall, J., Olsson, L.M., Kovatcheva-Datchary, P., Nilsson, S., Tremaroli, V., Simon, M.C., Kiilerich, P., Akrami, R., Krämer, M., Uhlén, M., Gummesson, A., Kristiansen, K., Dahlgren, J., Bäckhed, F. Cell Host Microbe (2021)
  Describing the establishment of the gut microbiota during the first five years of life.
• Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology.
  Molinaro, A., Bel Lassen, P., Henricsson, M., Wu, H., Adriouch, S., Belda, E., Chakaroun, R., Nielsen, T., Bergh, P.O., Rouault, C., André, S., Marquet, F., Andreelli, F., Salem, J.E., Assmann, K., Bastard, J.P., Forslund, S., Le Chatelier, E., Falony, G., Pons, N., Prifti, E., Quinquis, B., Roume, H., Vieira-Silva, S., Hansen, T.H., Pedersen, H.K., Lewinter, C., Sønderskov, N.B.; MetaCardis Consortium, Køber, L., Vestergaard, H., Hansen, T., Zucker, J.D., Galan, P., Dumas, M.E., Raes, J., Oppert, J.M., Letunic, I., Nielsen, J., Bork, P., Ehrlich, S.D., Stumvoll, M., Pedersen, O., Aron-Wisneswky, J., Clément, K., Bäckhed, F. Nature Communications (2020)
  Showing that imidazole propionate is elevated in patients with T2D and cardiovascular disease of different ethnicities.
• The gut microbiota in prediabetes and diabetes: a population-based cross-sectional study
  Wu, H., Tremaroli, V., Schmidt, C., Lundqvist, A., Olsson, L.M., Krämer, M., Gummesson, A., Perkins, R.,Bergström, G., Bäckhed, F. Cell Metabolism (2020)
  Largest study on diabetes and microbiome to date demonstrating that the microbiota is altered in pre-diabetes and type 2 diabetes independent of medication.
• Microbe-produced imidazole propionate impairs insulin signaling via p38g/p62/mTORC1
  Koh, A., Molinaro, A., Ståhlman, M., Khan, M.T., Schmidt, C., Mannerås-Holm, L., Wu, H., Carreras, A., Jeong, H., Olofsson, L., Bergh, P., Gerdes, V., Hartstra, A, de Brauw, D., Perkins, R., Nieuwdorp, M., Bergström, G., Bäckhed, F. Cell (2018)
  Identified imidazole propionate to be elevated in subjects with T2D as well as showing causality and identified the underlying signalling mechanism.

• Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug 
  Wu, H., Esteve, E., Tremaroli, V., Khan, M.T., Caesar, R., Mannerås-Holm, L., Ståhlman, M., Olsson, L.M., Serino, M., Planas-Fèlix, M., Xifra, G., Mercader, J.M., Torrents, D., Burcelin, R., Ricart, W., Perkins, R., Fernàndez-Real, J.M., Bäckhed, F. Nature Medicine (2017)
  Demonstrated that the antidiabetic drug metformin alters the microbiome and that this alteration contributes to improved glucose metabolism.
• Gut metagenome in European women with normal, impaired and diabetic glucose control  
  Karlsson, F., Tremaroli, V., Nookaew, I., Bergström, G., Behre, C. J., Fagerberg, B., Nielsen, J., Bäckhed, F. Nature (2013)
  Identified a diabetes associated microbiota and developed a model to classify patients from controls.
• The gut microbiota as an environmental factor that regulates fat storage 
  Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, CF., Gordon, J. I. Proceeding of National Academy of Sciences USA, PNAS (2004)
  First paper to demonstrate that the gut microbiota contributes to adiposity.